4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $310,752 | -28.9% | 24,411 | +1.0% | 0.00% | – |
| Q2 2023 | $436,860 | +259.6% | 24,176 | +242.0% | 0.00% | – |
| Q1 2023 | $121,499 | +92.2% | 7,068 | +148.3% | 0.00% | – |
| Q4 2022 | $63,210 | -15.7% | 2,846 | -69.7% | 0.00% | – |
| Q3 2022 | $75,000 | +13.6% | 9,387 | 0.0% | 0.00% | – |
| Q2 2022 | $66,000 | -47.2% | 9,387 | +13.9% | 0.00% | – |
| Q1 2022 | $125,000 | -30.9% | 8,240 | 0.0% | 0.00% | – |
| Q4 2021 | $181,000 | +21.5% | 8,240 | +49.7% | 0.00% | – |
| Q3 2021 | $149,000 | +645.0% | 5,505 | +576.3% | 0.00% | – |
| Q2 2021 | $20,000 | -41.2% | 814 | +2.8% | 0.00% | – |
| Q1 2021 | $34,000 | – | 792 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |